Camber Capital Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Camber Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,400,000	Closed	-$38.6M	–	44
2021 Q2	$38.6M	Buy	1,400,000 +250,000	+22%	+$4.91M	1.3%	29
2021 Q1	$19M	Buy	+1,150,000	New	+$26.2M	0.65%	31
2020 Q3	–	Sell	-1,000,000	Closed	-$17.9M	–	39
2020 Q2	$17.9M	Sell	1,000,000 -765,000	-43%	-$11.5M	1.03%	25
2020 Q1	$17.6M	Buy	1,765,000 +265,000	+18%	+$2.17M	1.05%	23
2019 Q4	$12.2M	Hold	1,500,000	–	–	0.62%	27
2019 Q3	$14.9M	Buy	+1,500,000	New	+$14.2M	0.78%	31

Camber Capital Management's TBIO Position: Q3 2021 in Review

Camber Capital Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 1,400,000 shares — an estimated $38.6M sold.

Camber Capital Management first reported a position in TBIO in Q3 2019 and held it in 6 quarters. The position peaked at $38.6M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Camber Capital Management reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Camber Capital Management sold 1,400,000 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $38.6M.
Camber Capital Management first reported a position in Translate Bio, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Camber Capital Management's Translate Bio, Inc. Common Stock position peaked at $38.6M in Q2 2021.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Camber Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.